

# TereoPneuma

## **FOR IMMEDIATE RELEASE**

Monday, September 29, 2014

### **The ReDe Mask™ Passes all IEC and ISO Safety Tests**

SAN DIEGO, CA September 29, 2014 - TereoPneuma, Inc., a CA based company, today announced that the ReDe Mask™ has successfully passed all electrical and biological safety tests as required by the IEC and ISO standards for medical equipment.

The ReDe Mask™ is a disposable, single use oxygen face mask and respiration monitor that simultaneously provides supplemental oxygen to patients while also detecting exhalation and displaying a visual signal of each exhalation. A three-color LED signaling system is used to indicate breathing events. A green indicator illuminates with each breath when the respiration rate is above 8 breaths per minute. A yellow indicator similarly illuminates with each breath when the respiration rate is 3 to 8 breaths per minute. A red indicator flashes rapidly when the breathing rate is less than 3 breaths per minute.

“We’re pleased that our inaugural product has passed all safety tests. We put a lot of time and energy into the careful development of the ReDe Mask™ over the past year.” said Warren G. Young, PhD, President/COO of TereoPneuma, Inc.

The IEC and ISO identify common elements of all medical device safety standards and recommend a specific logical order to address these within a risk management framework as specified in ISO 14971. IEC 60601-1 is the harmonized standard for medical electrical equipment recognized by public health authorities in most countries. The ReDe Mask™ was tested for basic safety requirements, essential performance, usability and EMC (electromagnetic compatibility).

### **About TereoPneuma**

TereoPneuma is a privately held medical device company in San Diego, CA whose mission is to develop novel high technology products in the field of anesthesia. TereoPneuma is Greek for “observe breathing”. TereoPneuma's first product - the ReDe Mask™ - is a disposable, single use oxygen face mask and respiration monitor that simultaneously provides supplemental oxygen to patients while also detecting exhalation and displaying a visual signal of each exhalation. Further, it provides a visual warning signal when no breath is detected for 7.5 seconds, and a more vivid visual warning signal when no breath is detected for 20 seconds. Detailed information on the Company is available at [www.tereopneuma.com](http://www.tereopneuma.com).

### **Contact:**

William J. Mazzei, MD, CEO  
TereoPneuma, Inc.  
[info@tereopneuma.com](mailto:info@tereopneuma.com)